Skip to main content

Maze Therapeutics, Inc 10-Q for FY2026 Q3

Maze Therapeutics, Inc. (MAZE)

10-Q 2026-11-09 For: 2026-09-30
View Original
Added on November 09, 2026

About this 10-Q

Maze Therapeutics, Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Maze Therapeutics reported positive MZE829 Phase 2 data in 15 patients, showing a clinically meaningful mean reduction in proteinuria without serious adverse events. Nine-month net loss was $116.9 million; cash and marketable securities totaled $477.0 million as of September 30, 2026. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$47.97M
compared with a net loss of $30.09M a year earlier
Diluted EPS
-$0.79
compared with -$0.66 a year earlier